* wall-street.cz is not responsible for the content in this press release.
RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company’s Chief Development Officer, Pamela Pavco, Ph.D., will be presenting at IBC’s 15th Annual TIDES: Oligonucleotide and Peptide Therapeutics Conference. The TIDES Summit is prominently known as the premier meeting place for the oligonucleotide and peptide discovery, development and manufacturing industries.
On Wednesday, May 15, 2013 at 4:15pm EDT, Dr. Pavco will deliver a speaker presentation entitled “Clinical Development of RXI-109 to Reduce Dermal Scarring”, during the Clinical Progress of Oligonucleotide Therapeutics session. Dr. Pavco’s presentation will be available on the Company’s website.
This conference is being held May 12-15, 2013 at the Hynes Convention Center, Boston, MA. For more information visit: http://www.ibclifesciences.com/TIDES Continue reading ‘RXi Pharmaceuticals to Present at IBC’s 15th Annual TIDES: Oligonucleotide and Peptide Therapeutics Conference’ »


